IKS073

Iksuda's first ProAlk-ADC program: a best-in-class ADC in IND-enabling studies for solid tumors.
IKS073 has been designed to provide a best-in-class therapy with raised TI and wider utility over in-clinic and on-market competitors - resulting from tumor-selective enzymatic release of Iksuda's protein alkylating payload, ProAlk.
Our ProAlk payload shows high activity across a broad range of tumors, with consistently low potency in the fM to pM range for cancers associated with an over-expression of B7H3.
Like all our ADCs, the payload is delivered via glucuronide-driven tumor-selective activation for added precision and safety.
In preclinical studies, IKS073 is associated with high anti-cancer activity across a range of relevant xenograft models, including NSCLC and TNBC. In toxicology studies in non-human primates, it is well tolerated at doses which far exceed those that induce efficacy in mouse xenografts, enabling a high, clinically relevant TI for onward testing in-clinic.
IKS073 contains Iksuda's PermaLink conjugation chemistry which ensure high ADC stability.

Keep informed
Sign up for our latest programme news and insights